0.66
-0.209(-24.02%)
Currency In USD
Address
420 Saw Mill River Road
Ardsley, NY 10502
United States of America
Phone
914 347 4300
Website
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
102
First IPO Date
February 10, 2006
| Name | Title | Pay | Year Born |
| Dr. Ron Cohen M.D. | Founder, Chief Executive Officer, President & Director | 984,150 | 1956 |
| Mr. Michael A. Gesser M.B.A. | Chief Financial Officer | 459,150 | 1963 |
| Mr. Kerry M. Clem | Chief Commercial Officer | 592,225 | 1970 |
| Mr. Neil S. Belloff Esq. | General Counsel & Corporate Secretary | 0 | 1960 |
| Ms. Denise J. Duca | Executive Vice President of Human Resources | 0 | N/A |
| Sofia Ali | Senior Vice President of Operations & Strategic Planning | 0 | N/A |
| Ms. Felicia Vonella | Vice President of Investor Relations | 0 | N/A |
| Mr. Andrew Mayer J.D. | Senior Vice President | 0 | N/A |
| Mr. Robert Morales | Interim Principal Accounting Officer, Principal Financial Officer, Vice President of Finance & Controller | 0 | 1968 |
| Ms. Tierney Saccavino | Executive Vice President of Corporate Communications | 0 | N/A |
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.